News

MedPage Today on MSN2d
Most Babies Protected Against RSV During First Season Immunization Was Available
During the first respiratory syncytial virus (RSV) season in which a maternal vaccine and a monoclonal antibody for infants ...
Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aide - report
CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.
Zacks Investment Research on MSN1d
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...
Morningstar21d
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...
24/7 Wall St. on MSN13d
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...
RSV vaccine to be available for vulnerable Australians aged 50 to 59
Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).
Dermatology Advisor1d
ACIP Recommends RSV Vaccine for 50 to 59-Year-Olds at High Risk
ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.
Seeking Alpha21d
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...